BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 36476351)

  • 61. The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer.
    Ren M; Song X; Niu J; Tang G; Sun Z; Li Y; Kong F
    Exp Cell Res; 2022 Oct; 419(2):113276. PubMed ID: 35863454
    [TBL] [Abstract][Full Text] [Related]  

  • 62. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Knockdown of Long Non-Coding RNA
    Zhan Y; Abuduwaili K; Wang X; Shen Y; Nuerlan S; Liu C
    Cancer Manag Res; 2020; 12():7725-7737. PubMed ID: 32943921
    [TBL] [Abstract][Full Text] [Related]  

  • 64. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 65. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer.
    Yuwen DL; Sheng BB; Liu J; Wenyu W; Shu YQ
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2650-2658. PubMed ID: 28678319
    [TBL] [Abstract][Full Text] [Related]  

  • 67. miR-125b reverses cisplatin resistance by regulating autophagy via targeting RORA/BNIP3L axis in lung adenocarcinoma.
    Liu L; Guo NA; Li X; Xu Q; He R; Cheng L; Dang C; Bai X; Bai Y; Wang X; Chen Q; Zhang LI
    Oncol Res; 2024; 32(4):643-658. PubMed ID: 38560570
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Propofol decreases cisplatin resistance of non-small cell lung cancer by inducing GPX4-mediated ferroptosis through the miR-744-5p/miR-615-3p axis.
    Han B; Liu Y; Zhang Q; Liang L
    J Proteomics; 2023 Mar; 274():104777. PubMed ID: 36427803
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis.
    Chen L; Han X; Hu Z; Chen L
    Cancer Chemother Pharmacol; 2019 May; 83(5):921-931. PubMed ID: 30859368
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mechanism of PWAR6 regulating cisplatin drug sensitivity in non-small cell lung cancer through miR-577/PHACTR1.
    Tang W; Luo J; Lin S; Xu J; Yan Q
    Gene; 2024 Jan; 893():147954. PubMed ID: 37923092
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Suppression of ZNF205-AS1/EGR4 positive feedback loop attenuates cisplatin resistance of non-small cell lung cancer cells via targeting miR-138-5p/OCT4 pathway.
    Li H; Jin Y; Zhu Y; Shen B; Xu Y
    J Thorac Dis; 2024 Jan; 16(1):296-310. PubMed ID: 38410545
    [TBL] [Abstract][Full Text] [Related]  

  • 72. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
    Ma Y; Li X; Cheng S; Wei W; Li Y
    Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
    [TBL] [Abstract][Full Text] [Related]  

  • 73. LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress.
    Ma P; Han W; Meng C; Tan X; Liu P; Dong L
    Anal Cell Pathol (Amst); 2022; 2022():6100176. PubMed ID: 36311891
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Blocking hsa_circ_0074027 suppressed non-small cell lung cancer chemoresistance via the miR-379-5p/IGF1 axis.
    Zheng S; Wang C; Yan H; Du Y
    Bioengineered; 2021 Dec; 12(1):8347-8357. PubMed ID: 34592879
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Circ_0004015 silencing represses cisplatin chemoresistance and tumor progression by reducing KLF8 in a miR-198-dependent manner in non-small cell lung cancer.
    Li Y; Yang X; Xiong X
    Genomics; 2022 Mar; 114(2):110294. PubMed ID: 35134495
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Exosome-Derived Circ-PVT1 Contributes to Cisplatin Resistance by Regulating Autophagy, Invasion, and Apoptosis Via miR-30a-5p/YAP1 Axis in Gastric Cancer Cells.
    Yao W; Guo P; Mu Q; Wang Y
    Cancer Biother Radiopharm; 2021 May; 36(4):347-359. PubMed ID: 32799541
    [No Abstract]   [Full Text] [Related]  

  • 77. [The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain].
    Ren L; Huang C; Liu YH; Yu Y; Lin L; Wen LJ
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1454-8. PubMed ID: 27266356
    [TBL] [Abstract][Full Text] [Related]  

  • 78. miR-129-2 upregulation induces apoptosis and promotes NSCLC chemosensitivity by targeting SOX4.
    Zhou W; Cai C; Lu J; Fan Q
    Thorac Cancer; 2022 Apr; 13(7):956-964. PubMed ID: 35146917
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Circ_0048856 competes with ABCC1 for miR-193a-5p/miR-98-5p binding sites to promote the cisplatin resistance and tumorigenesis in lung cancer.
    Liu L; Zhang Q; Peng H
    J Chemother; 2023 Feb; 35(1):39-52. PubMed ID: 35289739
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Knockdown of circLRWD1 weakens DDP resistance via reduction of SIRT5 expression through releasing miR-507 in non-small cell lung cancer.
    Deng Z; Tu Q; Hu G; Xing M
    Anticancer Drugs; 2022 Oct; 33(9):861-870. PubMed ID: 35946561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.